Kotsopoulos noted that BRCA carriers have a substantially increased lifetime risk of breast and ovarian cancer. Management of ...

OPM and OMB launch Federal HR 2.0 to unify HR systems into a single Core HCM platform and guide agencies through a two-wave ...

Talent teams plan to increase HR tech spending in 2026 as AI moves from experiment to infrastructure, according to a new ...

Patients with HER2-positive, hormone receptor (HR)-positive metastatic breast cancer can be safely treated without chemotherapy.

SAN ANTONIO -- The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first ...

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, ...

Abemaciclib monotherapy benefited 33% of patients with HR-positive, HER2-negative breast cancer post-CDK4/6 inhibitor progression. Abemaciclib shows promise as a monotherapy for HR-positive, ...

Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior ...

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, ...

Depression has been tied to a two-fold increased risk offor epilepsy and a suboptimal response to initial therapy, ...

Companies are investing in people analytics tools, people analytics software, and HR analytics software because the importance of HR analytics has never been higher.

Treatment with an aromatase inhibitor improves outcomes at 10 years compared to treatment with a SERM in HR+, HER2+ early breast cancer.